REBYOTA for the Prevention of Recurrence of Clostridioides Difficile Infection (rCDI) in Adult Patients: An Observational Study

Brief description of study

The purpose of this research study is to better understand how well the medication REBYOTA is working to prevent recurrence of Clostridioides Difficile Infection (CDI) among adults following antibiotic treatment. CDI is an infection in the colon caused by the bacteria clostridium difficile. The study also aims to understand patient-reported outcomes and health care utilization (e.g., doctor visits, hospitalizations) after receiving REBYOTA in a real-world setting.

Clinical Study Identifier: s23-00533
Principal Investigator: Jordan E Axelrad.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.